Impact of intestinal failure and parenteral support on adult patients with short-bowel syndrome: A multinational, noninterventional, cross-sectional survey

Autor: Palle B. Jeppesen, Saeid Shahraz, Thomas Hopkins, Andrew Worsfold, Elisabeth Genestin

Publikováno v: Jeppesen, P B, Shahraz, S, Hopkins, T, Worsfold, A & Genestin, E 2022, ' Impact of intestinal failure and parenteral support on adult patients with short-bowel syndrome : A multinational, noninterventional, cross-sectional survey ', Journal of Parenteral and Enteral Nutrition, vol. 46, no. 7, pp. 1650-1659 . https://doi.org/10.1002/jpen.2372

Background: Patients with short-bowel syndrome and intestinal failure (SBS-IF) require parenteral support (PS) and experience various symptoms and comorbidities. This survey assessed the impact of SBS-IF and PS on patients and their health-related qu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e56dc2b9f06659faa1d59a61cddf1cb5
https://pubmed.ncbi.nlm.nih.gov/35289416

The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

Autor: Philippe Rougier, Jean-Alain Chayvialle, Philippe Ruszniewski, Pascal Hammel, Denis Cloarec, Raymond Jian, Jean Michel Raymond, Henri Michel, Jean-Louis Dupas, Michel Ducreux, Joëlle Blumberg, Elisabeth Genestin, Hervé Gouerou

Publikováno v: The American Journal of Gastroenterology. 95:3276-3281

Somatostatin analogs are the first-line drugs for controlling hormone-mediated symptoms of carcinoid tumors. Prospective and retrospective studies have suggested that somatostatin analogs also have antiproliferative activity. The octapeptide lanreoti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ad377538c5a83831cbe4cc72c0bd1b6
https://doi.org/10.1111/j.1572-0241.2000.03210.x